Q-omics provides the consensus-scored MSRB1 profile across patient tissues and cancer cell-line models. MSRB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MSRB1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MSRB1 RNA expression shows 18,092 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where MSRB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSRB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSRB1 survival associations across molecular data types. MSRB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSRB1 RNA expression–survival associations across cancer types. High MSRB1 expression shows unfavorable associations in UVM, UCS, LGG, ACC and READ, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MSRB1 RNA expression.
This table summarizes MSRB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MSRB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSRB1 shows lower tumor expression in KICH and CHOL and higher tumor expression in COAD, LUAD, HNSC and BRCA. The KICH box plot shows higher MSRB1 RNA expression in normal versus tumor tissue (log2 FC = −2.476, t-test p < 0.001).
This table shows molecular features associated with MSRB1 in patient tissues and cancer cell lines. In patient samples, MSRB1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSRB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
